Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 4/20 | 0.48 |
| ▸ | AKT2 | P31751 | 4/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23000963 | 1.00 | CETP (0.53) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL17817032 | 1.00 | CETP (0.53) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL14666330 | 1.00 | CETP (0.53) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL17188245 | 1.00 | CETP (0.53) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL14666253 | 0.92 | LGALS8 (0.56) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL17188247 | 0.92 | LGALS8 (0.56) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL14666207 | 0.91 | MAPK1 (0.46) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL10782436 | 0.90 | CETP (0.53) | CETPMAPK1 | |
| SCHEMBL3015938 | 0.90 | CETP (0.53) | CETPMAPK1 | |
| SCHEMBL19874824 | 0.90 | CETP (0.53) | CETPMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189438-A1 | DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells | THE UNIV OF MANITOBA (CA) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189438-A1 | DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells | UGCG, PNLIP, B3GAT3 | CETP 253/4885AKT1 1787/4885AKT2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.